이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BioHarvest Sciences 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ilan Sobel

최고 경영자

US$481.6k

총 보상

CEO 급여 비율	n/a
CEO 임기	4.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	4.1yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO

Ilan Sobel

4.1yrs

테뉴어

US$481,581

보상

Mr. Ilan Sobel has been the Chief Executive Officer at BioHarvest Sciences Inc. since June 9, 2020. He served as Chief Operating Officer at Weissbeerger Ltd. and then Chief Commercial Officer of Weissbeerg...

리더십 팀

이름	위치	테뉴어	보상	소유권
Zaki Rakib	Co-Founder	5.8yrs	US$1.16m	데이터 없음
Ilan Sobel	Chief Executive Officer	4.1yrs	US$481.58k	데이터 없음
Yochi Hagay	Co-Founder	5.8yrs	US$67.02k	데이터 없음
Alan Rootenberg	Chief Financial Officer	5.8yrs	US$31.48k	데이터 없음
Ilana Belzer	Chief Operating Officer	1.3yrs	US$275.09k	0.0032% $ 3.0k
David Ryan	VP of Investor Relations	11.3yrs	US$44.45k	0.23% $ 216.5k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	2.3yrs	US$421.35k	0.015% $ 14.3k
Matthew Zrebiec	Vice President of Business Development	less than a year	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: 8MV0 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zaki Rakib	Co-Founder	5.8yrs	US$1.16m	데이터 없음
Yochi Hagay	Co-Founder	3.5yrs	US$67.02k	데이터 없음
David Ryan	VP of Investor Relations	11.3yrs	US$44.45k	0.23% $ 216.5k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	1.5yrs	US$421.35k	0.015% $ 14.3k
Vincent Giampapa	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Dennis Goodman	Member of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
David Tsur	Independent Non-Executive Director	2.8yrs	US$37.36k	데이터 없음
David Brady	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Scott McCune	Member of Advisory Board	3.3yrs	데이터 없음	데이터 없음
Vivien Rakib	Independent Director	5.8yrs	US$26.65k	17.5% $ 16.8m
John Fiddick	Independent Director	5.4yrs	US$26.65k	데이터 없음
Roberto Chait	Member of Advisory Board	3.8yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 8MV0 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

BioHarvest Sciences 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

No independent directors

BioHarvest Sciences Inc. Appoints Gavriel Lambert to its Board of Advisors

Recent updates

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in funding

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023)

Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022)

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024

BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding

Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.009 loss in 3Q 2022)

Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding

Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022)

BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in funding

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022)

Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021)

BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic Neuritis

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

BioHarvest Sciences Inc. announced that it has received CAD 10.03355 million in funding

Bioharvest Sciences Inc. Provides Revenue Guidance for the Year 2022 and 2023

Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021)

BioHarvest Sciences Inc. Appoints Gavriel Lambert to its Board of Advisors

Bioharvest Sciences Inc. Hires Dr. Brian S. Cornblatt as Chief Medical Officer

First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021)

Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020)

No independent directors

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.3 million in funding

BioHarvest Sciences Inc. Reiterates Sales Orders Guidance for 2022

BioHarvest Sciences Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020)

Bioharvest Sciences Inc. Unveils New Groundbreaking Cannabis Trichome Structure

BioHarvest Sciences Inc. announced that it expects to receive CAD 4 million in funding

BioHarvest Sciences Inc. Reveals Vinia Anti-Aging Capabilities Via Blood Flow Improvement

First quarter 2021 earnings released

Full year 2020 earnings released

Bioharvest Sciences Inc. Unveils Unique Polyphenolic Content of Its Upcoming Olive Based Nutraceutical

Bioharvest Sciences Inc. Announces Partnership with Boldt and Summit Strategy Group to Develop A Sustainability Framework and Esg Report

BioHarvest Sciences Inc. Announces a Major Breakthrough in the Growth of Cannabis TRICHOMES across Multiple Strains in Liquid Media

BioHarvest Sciences Inc. announced that it has received CAD 6.179932 million in funding

BioHarvest Sciences Inc. announced that it expects to receive CAD 6 million in funding

BioHarvest Sciences Inc. Appoints Dennis Goodman to Its Scientific Advisory Board

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령